



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
2 Peachtree Street – **5th Floor Board Room**
Atlanta, Georgia 30303

June 16, 2016



**GEORGIA DEPARTMENT
OF COMMUNITY HEALTH**

This page intentionally left blank



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

2 Peachtree Street - 5th Floor DCH Board Room

Atlanta, Georgia 30303

Thursday, June 16, 2016

9:30 a.m. to 1:00 p.m.

CALL TO ORDER	<i>Gurinder Doad, MD, Chair</i>
COMMENTS FROM THE DEPARTMENT	<i>Peter D'Alba, RPh, Pharmacy Director, DCH</i>
MINUTES FROM PREVIOUS MEETING	<i>Chair</i>
EXTERNAL COMMENTS SESSION	<i>Chair</i>
CLINICAL REVIEWS	<i>Afzal Mistry, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ New Drugs	
● Orkambi	
● Tresiba	
● Uptravi	
● Viberzi	
➤ Therapeutic Class	
● Multiple Sclerosis	
➤ Supplemental Rebate Classes	
ADJOURNMENT OF OPEN SESSION	<i>Chair</i>
EXECUTIVE SESSION	<i>Steve Liles, PharmD, Senior Director, Goold</i>
RECONVENING OF OPEN SESSION	<i>Chair</i>
BOARD'S RECOMMENDATIONS AND VOTES	<i>Chair</i>
FUTURE AGENDA ITEMS	<i>Chair</i>
ADJOURNMENT OF MEETING	<i>Chair</i>

This page intentionally left blank

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Thursday, March 17, 2016**

MEMBERS PRESENT

Gurinder J.S. Doad, M.D., Chair
Deborah Fincher, M.S., R.Ph., Vice Chair
Mia Avery, Pharm.D.
Douglas Collins, M.D.
Rod M. Duraski, M.D., FACP, MBA
M. Celeste Fowler, Pharm.D.
Yolanda P. Graham, M.D.
Robyn Lorys, Pharm.D.
J. Russell May, Pharm.D.
Brent L. Rollins, R.Ph., Ph.D.
Robert E. Shervette III, M.D.
Danny A. Toth, R.Ph.

MEMBERS ABSENT

Mary S. Harris, Ph.D.
Burton L. Lesnick, M.D., FAAP
Osgood (Drew) A. Miller, R.Ph.

Staff

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services
Turkesia Robertson-Jones, Pharm.D., Pharmacy Operations Manager, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, Pharmacy Services
Patricia Z. Jeter, MPA, R.Ph., Pharmacist, Pharmacy Services
Christian Malone, Pharm.D. Candidate (FAMU)

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President
Afzal "Fez" Mistry, Pharm.D., Clinical Pharmacist
Nekia Austin, Pharm.D., Esq., CFE, Program Compliance Director
Chad Nicholson, Pharm.D., Clinical Pharmacist

OptumRx

Susan McCreight, Sr. Director, Public Sector Account Management
Mark Hall, MBA, PMP, Account Manager
Talmahjia "Tami" Sweat, Pharm.D., Clinical Systems Product Manager

Goold Health Services

Steve Liles, Pharm.D., Sr. Director, Pharmacy Services
Doug Martin, Pharm.D., Pharmacy Project Manager

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its first meeting for the calendar year on March 17, 2016. The Chair, Gurinder J.S. Doad, M.D., called the meeting to order at 9:09am. He thanked Tara Cockerham, Pharm.D., for her years of service to the Board and congratulated Afzal “Fez” Mistry, Pharm.D., and Chad Nicholson, Pharm.D., for their work and continued service.

Comments from the Department

Peter D’Alba, R.Ph., Pharmacy Director, Pharmacy Services, commented on the following items:

- NorthStar –Chad Nicholson, Pharm.D., was welcomed as a new pharmacist and Afzal “Fez” Mistry, Pharm.D., was congratulated for becoming the new account lead.

Acknowledgements

Board members introduced themselves. The following pharmacy students were acknowledged: Janushi Pandya (UGA), Saad Khan (UGA), Ebony Darden (PCOM), Kinela Naidu (PCOM), Young Park (PCOM), Erika Tillery (Mercer), and Christian Malone (FAMU).

Minutes from the Previous Meeting

Chair Doad asked for corrections or changes to the minutes from the December 15, 2015 meeting. There were no corrections. A motion was made (J. Russell May, Pharm.D), seconded, and carried to approve the minutes as written.

External Comments Session

External comments were presented to the Board from the following:

- Adefisayo Oduwole, MD, Cardiologist, Morehouse School of Medicine – spoke about Entresto
- Afzal “Fez” Mistry, Pharm.D., provided an overview of written comments received by Joseph Payne, M.D., Dermatology Associates of Atlanta, requesting preferred status for Cosentyx.

Disclosure forms were completed by Adefisayo Oduwole, M.D., and Joseph Payne, M.D, and were reviewed by the Department.

Manufacturers’ Forum

Afzal “Fez” Mistry, Pharm.D., noted the one page summaries from the Manufacturer’s Forum were sent electronically to DURB members for review. There were no questions or comments.

The next forum will be held on Thursday, May 12, 2016 from 9am-5pm at the NorthStar Healthcare Consulting office: 1121 Alderman Drive, Suite 112, Alpharetta, GA 30005.

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Thursday, March 17, 2016
New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Vasoprotectants	<i>Corlanor</i>	Afzal Mistry, Pharm.D.
Cardiovascular, Angiotensin Modulator/Nepriylsin Inhibitor	<i>Entresto</i>	Afzal Mistry, Pharm.D.
Antivirals, Hepatitis C	<i>Daklinza, Technivie, Zepatier</i>	Afzal Mistry, Pharm.D.
Antihyperlipidemics, PCSK9 Inhibitors	<i>Praluent, Repatha</i>	Afzal Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Entresto – PARADIGM trial used enalapril which is typically first line therapy; concerns of long-term use effects on macular degeneration and Alzheimer’s; potential for other indications
- Daklinza, Technivie, Zepatier – cost of polymorphism test (~\$800) and 12 vs.16 weeks of treatment; impact of these drugs-look at compliance, follow-up testing, further treatment
- Praluent, Repatha – exclusions of statins in certain studies

Therapeutic Class Reviews

Clinical information for the following therapeutic classes was presented for discussion by Dr. Afzal “Fez” Mistry. The complete detailed therapeutic class review was provided in the Therapeutic Class Review section of the DUR Board binder.

Therapeutic Class Name
Atypical Antipsychotics
Antihemophilic Recombinant Factor VIII
Antihemophilic Recombinant Factor IX

Questions and comments were made from the Board on the following:

- Abilify – approved for Tourette’s; look at cost effectiveness of quantity limits

Thursday, March 17, 2016

- Second generation agents – improved side effects; trend now is long-acting agents to improve compliance; all require prior authorization- can be challenging when treating outside of FDA indications
- Factor VIII – studies in progress to determine if using longer acting agents is more cost effective; longer acting agents have less frequent dosing but price may negate benefit; prophylaxis started around first bleed
- Factor IX – major difference in half-life with newer products; cost is a factor; longer half-life products should be considered in children; 10 day recommendation factors in higher clearance in children; newer agents have less inhibitors

Supplemental Rebate Drugs – New Clinical Information Review

Clinical updates to the Supplemental Rebate categories were listed in the Supplemental Rebate section of the DURB binder and presented to the Board by Dr. Afzal “Fez” Mistry. The following therapeutic categories had updates:

Drug Class/Name
Antihemophilic Products for von Willebrand
Anticoagulants
Attention Deficit Hyperactivity Disorder (ADHD) Agents
Biologic Immunomodulators

Questions and comments were made from the Board on the following:

ADHD – efficacy similar across agents; helpful to have different formulations for children

DCH Decisions

DCH Decisions from the December 2015 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Future Agenda Items

There were no future agenda items noted.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Thursday, June 16, 2016

Tuesday, September 13, 2016

Tuesday, December 13, 2016

- Manufacturers’ Forum

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES

Thursday, March 17, 2016

NorthStar Healthcare Consulting
1121 Alderman Drive
Suite 112
Alpharetta, Georgia 30005

Thursday, May 12, 2016
Thursday, August 11, 2016
Thursday, November 10, 2016

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Goold Health Services, NorthStar HealthCare Consulting, and OptumRx. Pharmacy students, Janushi Pandya (UGA), Saad Khan (UGA), Ebony Darden (PCOM), Kinela Naidu (PCOM), Young Park (PCOM), Erika Tillery (Mercer), and Christian Malone (FAMU), attended the closed session with Board members. A motion was made by Douglas Collins, M.D., and seconded by Robyn Lorys, Pharm.D., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Gurinder J.S. Doad, M.D., adjourned the open session at approximately 10:37 am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 10:53am to 12:07pm.

Reconvening of Open Session

The DUR Board reconvened for the open session at 12:13pm.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL). All motions and votes are noted in Attachment A.

New Drugs and Supplemental Rebate Classes

Vasoprotectants

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Corlanor (Oral) Tablet*.

Cardiovascular-Angiotensin Modulator/Neprilysin Inhibitor

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Entresto (Oral) Tablet*.

Antivirals, Hepatitis C Virus, Direct-Acting Antivirals

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Technivie (Oral) Tablet*, *Viekira Pak (Oral) Tablet*, and *Zepatier (Oral) Tablet*.

Antihyperlipidemics, PCSK9 Inhibitors and Homozygous Familial Hypercholesterolemia Drugs

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Repatha (Subcutaneous) Injection*, and *Non-Preferred* status with *Prior Authorization* for *Praluent (Subcutaneous) Injection*.

Antipsychotics, Atypical Oral

The DUR Board deferred providing recommendations until the June 2016 DURB meeting.

Antihemophilic Products, Factor VIII Recombinant

The DUR Board recommended *Preferred* status for *Helixate FS (Intravenous) Vial* and *Non-Preferred* status with *Prior Authorization and Grandfathering* for all other agents in the class, including new drugs *Adynovate (Intravenous) Vial* and *Nuwiq (Intravenous) Vial*.

Antihemophilic Products, Factor IX Recombinant

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Benefix (Intravenous) Vial* and *Non-Preferred* status with *Prior Authorization and Grandfathering* for all other agents in the class.

Antihemophilic Products, von Willebrand Factor

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Wilate (Intravenous) Vial* and *Non-Preferred* status with *Prior Authorization* for all other agents in the class.

Aminoglycosides, Cystic Fibrosis

The DUR Board recommended *No Changes* in the class.

Anticoagulants

The DUR Board recommended *Preferred* status for *Eliquis (Oral) Tablet, Pradaxa (Oral) Capsule, and Xarelto (Oral) Tablet*.

Anticonvulsants, Benzodiazepines

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Onfi (Oral) Tablet*.

Anticonvulsants, New Generation

The DUR Board recommended *No Changes* in the class.

Antiinflammatory, Antirheumatic Antimetabolites

The DUR Board recommended *No Changes* in the class.

Attention-Deficit Hyperactivity Disorder Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Kapvay (Oral) Tablet, Methylin (Oral) Solution, and Methylphenidate LA (Oral) Capsule* and *Non-Preferred* status with *Prior Authorization* for *Dexedrine (Oral) Capsule ER and Tablet*.

Biologic Immunomodulators

The DUR Board recommended *No Changes* in the class.

Gastrointestinal, Digestive Enzymes

The DUR Board recommended *No Changes* in the class.

Growth Hormone

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Genotropin (Subcutaneous) Injection*.

Phosphate Binder Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Calcium Acetate (Oral) Capsule*.

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Doad adjourned the meeting at 12:26pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2016.

Gurinder J.S. Doad, M.D., Chair

DRAFT

To: Drug Utilization Review Board Members

From: Joseph Payne MD, Dermatology Associates of Atlanta

I am a community dermatologist who specializes in treating psoriasis. I work in a large group practice in Atlanta which serves many patients with Medicaid. I am an advocate for my patients and I utilize EVERY literature-supported drug and device in the treatment of psoriasis.

Psoriasis can be a devastating disease for patients. The overall psoriasis population is quite large – 1 to 2% of the US population. Although severe forms make up a minority of the disease, this still is a large number of people. Having psoriasis affects every facet of life. The medical effects and time spent on twice daily treatment can be significant. But the impact on social and work life is probably most significant. This may help to explain high rates of depression and suicide. Patients with significant hand or foot psoriasis may have difficulty performing their jobs or even walking. The appearance of the disease affects every interpersonal relationship whether in business or personal life. I have had patients talk about people moving away from them in the elevator as well as being asked to leave community pools. Patients who are involved in sales have an especially difficult time.

The biologic medicines have revolutionized the treatment of psoriasis over the last decade. I can now confidently tell patients that they will be clear or almost clear because of the number and efficacy of the options available. The medicines that are currently preferred on the Medicaid formulary (Enbrel and Humira) are good medicines. They are both within the TNF alpha blocker class of medicines and have efficacy against psoriasis and psoriatic arthritis. However, I am hopeful that you will add Cosentyx to the list. Cosentyx represents a novel class of biologic medicines for psoriasis (IL-17 blockers). Cosentyx has shown unsurpassed efficacy in the treatment of psoriasis. Novartis is the first manufacturer to perform comparative trials against other current biologic medicines. In these trials they clearly showed superiority to both Enbrel (77% vs 44% PASI75 at week 12 in FIXTURE study) and Stelara (79% vs 57.6% PASI90 at week 16 in CLEAR study). I have been treating several patients successfully with Cosentyx since its approval – all with no safety issues.

Again, I strongly implore the board to add this extremely effective new class of biologic to the preferred formulary to allow for better clearance of this devastating illness.

RECEIVED

SEP 26 2015

Chief's Office
13 Medicaid Division

Drug Utilization Review Board

Motions - Votes - **New Drugs**

March 17, 2016

New Drug		Drug	PDL Status	Motion - Recommendations		Additional Comments
Vasoprotectants		CORLANOR (ORAL) TABLET	NPPA	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.	√		√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.		√	√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

March 17, 2016

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Cardiovascular, Angiotensin Modulator/Neprilysin Inhibitor	ENTRESTO (ORAL) TABLET	NPPA	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.	√		√		
4 Doad, Gurinder J.S., M.D.- Chair			√		
5 Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.			√		
8 Lorys, Robyn Pharm.D.		√	√		
9 May, J. Russell (Rusty)			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Shervette III, Robert E., M.D.			√		
12 Toth, Danny, R.Ph.			√		
TOTAL			12	0	0
Board Members - Absent					
1 Harris, Mary, Ph.D.					
2 Lesnick, Burton, M.D.					
3 Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

March 17, 2016

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antivirals, Hepatitis C Virus, Direct-Acting Antivirals	DAKLINZA (ORAL) TABLET	NPPA	NPPA		
	TECHNIVIE (ORAL) TABLET	PPA	PPA		
	VIEKIRA PAK (ORAL) TABLET	NPPA	PPA	Not a new drug	
	ZEPATIER (ORAL) TABLET	NPPA	PPA		
Board Members - Present <i>(Strike out, when absent)</i>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D. - Chair			√		
5 Fincher, Deborah W., M.S., R.Ph. - Vice		√	√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.			√		
8 Lorys, Robyn Pharm.D.	√		√		
9 May, J. Russell (Rusty)			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Shervette III, Robert E., M.D.			√		
12 Toth, Danny, R.Ph.			√		
TOTAL			12	0	0
Board Members - Absent					
1 Harris, Mary, Ph.D.					
2 Lesnick, Burton, M.D.					
3 Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

March 17, 2016

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antihyperlipidemics, PCSK9 Inhibitors	PRALUENT PEN (SUB-Q) PEN INJECTION	NPPA	NPPA		
	PRALUENT SYRINGE (SUB-Q) SYRINGE	NPPA	NPPA		
	REPATHA SURECLICK (SUB-Q) PEN INJECTION	NPPA	PPA		
	REPATHA SYRINGE (SUB-Q) SYRINGE	NPPA	PPA		
Board Members - Present <i>(Strike out, when absent)</i>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.		√	√		
4 Doad, Gurinder J.S., M.D.- Chair			√		
5 Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.			√		
8 Lorys, Robyn Pharm.D.			√		
9 May, J. Russell (Rusty)	√		√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Shervette III, Robert E., M.D.			√		
12 Toth, Danny, R.Ph.			√		
TOTAL			12	0	0
Board Members - Absent					
1 Harris, Mary, Ph.D.					
2 Lesnick, Burton, M.D.					
3 Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

March 17, 2016

New Drug	Drug	PDL Status	Recommendation		
Antipsychotics, Atypical Oral	REXULTI (ORAL) TABLET	NPPA	Deferred for class review in June		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D.- Chair			√		
5 Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.	√		√		
8 Lorys, Robyn Pharm.D.			√		
9 May, J. Russell (Rusty)			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Shervette III, Robert E., M.D.		√	√		
12 Toth, Danny, R.Ph.			√		
		TOTAL	12	0	0
Board Members - Absent					
1 Harris, Mary, Ph.D.					
2 Lesnick, Burton, M.D.					
3 Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board
Motions - Votes - **Therapeutic Class Review**
March 17, 2016

Therapeutic Class Review		Recommendation				
Atypical Antipsychotics,		Board deferred the entire class review until June 2016				
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.	√		√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.		√	√		
12	Toth, Danny, R.Ph.			√		
		TOTAL		12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board
Motions - Votes - **Therapeutic Class Review**
March 17, 2016

Therapeutic Class Review		Recommendation				
Antihemophilic Factor VIII Recombinant		Preferred status for Helixate FS (Intravenous) Vial .				
		Non-Preferred status with Prior Authorization and Grandfathering for all other agents in the class, including new drugs Adynovate (Intravenous) Vial and Nuwiq (Intravenous) Vial .				
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		√	√		
2	Collins, Douglas, M.D.	√		√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board
Motions - Votes - **Therapeutic Class Review**
March 17, 2016

New Drug		Recommendation				
Antihemophilic Factor IX Recombinant		Preferred status with Prior Authorization for Benefix (Intravenous) Vial.				
		Non-Preferred status with Prior Authorization and Grandfathering for all other agents in the class.				
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.	√		√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.		√	√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antihemophilic Products, von Willebrand Factor		ALPHANATE (INTRAIVEN) VIAL	P	NPPA	Grandfathering for this product	
		HUMATE-P (INTRAIVEN) KIT	P	NPPA	Grandfathering for this product	
		WILATE (INTRAIVEN) KIT	P	P		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.	✓		✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Chair			✓		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.			✓		
8	Lorys, Robyn Pharm.D.			✓		
9	May, J. Russell (Rusty)			✓		
10	Rollins, Brent L., R.Ph., Ph.D.			✓		
11	Shervette III, Robert E., M.D.			✓		
12	Toth, Danny, R.Ph.			✓		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Recommendation				
Aminoglycosides, Cystic Fibrosis		No changes to the drugs in this class				
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.	✓		✓		
2	Collins, Douglas, M.D.			✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Chair			✓		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.			✓		
8	Lorys, Robyn Pharm.D.			✓		
9	May, J. Russell (Rusty)		✓	✓		
10	Rollins, Brent L., R.Ph., Ph.D.			✓		
11	Shervette III, Robert E., M.D.			✓		
12	Toth, Danny, R.Ph.			✓		
		TOTAL		12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Anticoagulants		ELIQUIS (ORAL) TABLET	NPPA	P		
		PRADAXA (ORAL) CAPSULE	NPPA	P		
		XARELTO (ORAL) TABLET	NPPA	P		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.		√	√		
9	May, J. Russell (Rusty)	√		√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Anticonvulsants, Benzodiazepines		ONFI (ORAL) TABLET	PPA	NPPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Chair			✓		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.	✓		✓		
8	Lorys, Robyn Pharm.D.			✓		
9	May, J. Russell (Rusty)			✓		
10	Rollins, Brent L., R.Ph., Ph.D.			✓		
11	Shervette III, Robert E., M.D.			✓		
12	Toth, Danny, R.Ph.			✓		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Recommendation				
Anticonvulsants, New Generation		No changes to the drugs in this class				
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.		√	√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.	√		√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
		TOTAL		12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Recommendation			
Antiinflammatory, Antirheumatic Antimetabolites		No changes to the drugs in this class			
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES	
				YES (v)	NO (v)
				ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			√	
2	Collins, Douglas, M.D.			√	
3	Duraski, Rod, M.D.			√	
4	Doad, Gurinder J.S., M.D.- Chair			√	
5	Fincher, Deborah W., M.S., R.Ph. - Vice	√		√	
6	Fowler, M. Celeste, Pharm.D.			√	
7	Graham, Yolanda, M.D.			√	
8	Lorys, Robyn Pharm.D.			√	
9	May, J. Russell (Rusty)		√	√	
10	Rollins, Brent L., R.Ph., Ph.D.			√	
11	Shervette III, Robert E., M.D.			√	
12	Toth, Danny, R.Ph.			√	
			TOTAL	12	0
Board Members - Absent					
1	Harris, Mary, Ph.D.				
2	Lesnick, Burton, M.D.				
3	Miller, Osgood (Drew) A. R.Ph.				

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Attention-Deficit Hyperactivity Disorder Agents		KAPVAY (ORAL) TAB ER	NPPA	PPA		
		METHYLIN (ORAL) SOLUTION	NPPA	PPA		
		METHYLPHENIDATE LA (ORAL) CPBP	NPPA	PPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.	√		√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.		√	√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments		
Attention-Deficit Hyperactivity Disorder Agents		DEXEDRINE (ORAL) CAPSULE ER	PPA	NPPA			
		DEXEDRINE (ORAL) TABLET	PPA	NPPA			
Board Members - Present					VOTES		
<i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			√			
2	Collins, Douglas, M.D.			√			
3	Duraski, Rod, M.D.			√			
4	Doad, Gurinder J.S., M.D.- Chair			√			
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√			
6	Fowler, M. Celeste, Pharm.D.			√			
7	Graham, Yolanda, M.D.	√		√			
8	Lorys, Robyn Pharm.D.		√	√			
9	May, J. Russell (Rusty)			√			
10	Rollins, Brent L., R.Ph., Ph.D.			√			
11	Shervette III, Robert E., M.D.				√		
12	Toth, Danny, R.Ph.			√			
			TOTAL	11	1	0	
Board Members - Absent							
1	Harris, Mary, Ph.D.						
2	Lesnick, Burton, M.D.						
3	Miller, Osgood (Drew) A. R.Ph.						
Supplemental Rebate Class		Recommendation					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Biologic Immunomodulators		No changes to the drugs in this class				
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.	√		√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.		√	√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
TOTAL				12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Recommendation				
Gastrointestinal, Digestive Enzymes		No changes to the drugs in this class				
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		✓	✓		
2	Collins, Douglas, M.D.			✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Chair			✓		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.			✓		
8	Lorys, Robyn Pharm.D.			✓		
9	May, J. Russell (Rusty)			✓		
10	Rollins, Brent L., R.Ph., Ph.D.			✓		
11	Shervette III, Robert E., M.D.			✓		
12	Toth, Danny, R.Ph.	✓		✓		
TOTAL				12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Growth Hormone		GENOTROPIN (SUB-Q)	PPA	NPPA		
Board Members - Present <i>(Strike out when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.	√		√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.		√	√		
11	Shervette III, Robert E., M.D.				√	
12	Toth, Danny, R.Ph.			√		
			TOTAL	11	1	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

Drug Utilization Review Board

Motions - Votes - SR Class Review

March 17, 2016

Supplemental Rebate Class		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Phosphate Binder Agents		CALCIUM ACETATE (ORAL) CAPSULE	P	NPPA		
Board Members - Present		Motion Maker (√)	Seconded By (√)	VOTES		
<i>(Strike out, when absent)</i>				YES (√)	NO (√)	ABSTAIN (√)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.		√	√		
4	Doad, Gurinder J.S., M.D.- Chair			√		
5	Fincher, Deborah W., M.S., R.Ph. - Vice			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Lorys, Robyn Pharm.D.	√		√		
9	May, J. Russell (Rusty)			√		
10	Rollins, Brent L., R.Ph., Ph.D.			√		
11	Shervette III, Robert E., M.D.			√		
12	Toth, Danny, R.Ph.			√		
			TOTAL	12	0	0
Board Members - Absent						
1	Harris, Mary, Ph.D.					
2	Lesnick, Burton, M.D.					
3	Miller, Osgood (Drew) A. R.Ph.					

This page intentionally left blank

Important Update DCH Decision Document

**Listed below are Preferred Drug List changes for the State of Georgia
Fee-For-Service Medicaid and PeachCare for Kids Programs**

EFFECTIVE July 1, 2016 (see chart below)

DCH rebate vendor Goold Health Systems (GHS) has reviewed SFY2017 supplemental rebate offers with DCH and reviewed the below drug categories at the March 2016 DURB meeting. The PDL decisions or PDL changes for new drugs or categories reviewed during the March DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
ADHD AGENTS		
	ADDERALL XR	DEXEDRINE TAB, CAP ER
	FOCALIN, XR	DYANAVEL XR
	KAPVAY	PROCENTRA (ORAL) SOLUTION
	METHYLIN SOLN	
	METHYLPHENIDATE LA	
	QUILLIVANT XR	
	QUILLICHEW	
	VYVANSE	
AMINOGLYCOSIDES FOR CYSTIC FIBROSIS		
	KITABIS PAK	BETHKIS
		TOBI PODHALER
ANTICOAGULANTS		
	ELIQUIS	LOVENOX
	PRADAXA	SAVAYSA
	XARELTO	
ANTICONSULSANTS		
	LYRICA CAPS	APTIOM
	OXTELLAR XR	LYRICA SOLN
	VIMPAT	
ANTICONSULSANTS - BENZODIAZEPINES		
	DIASTAT	ONFI TAB, SUSP
ANTIHYPERLIPIDEMICS, PCSK9I		
	REPATHA	PRALUENT
ANTI-INFLAM, ANTIRHEUM ANTIMETAB		
		RASUVO
ANTIVIRALS, HEPATITIS C DAAS		
	HARVONI	DAKLINZA
	SOVALDI	OLYSIO
	TECHNIVIE	

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
	VIEKIRA PAK	
	ZEPATIER	
BIOLOGIC IMMUNOMODULATORS		
	COSENTYX	XELJANZ
	ENBREL	
	HUMIRA	
CV- ANGIOTENSIN RECPTOR BLOCKERS		
		DIOVAN
CV- BETA BLOCKERS		
		BYSTOLIC
CV-ANGIOTENSIN MODULATOR/NEPRILYSIN INHIBITOR		
		ENTRESTO
DERM, HYDROCORTISONE SOLN		
		TEXACORT
DERM, NSAIDS		
		FLECTOR
DERM, SCABICIDES,PEDICULOCIDES		
	SKLICE	NATROBA
FIBROMYALGIA AGENTS		
		SAVELLA
GI- DIGESTIVE ENZYMES		
	CREON	PERTZYE
		ZENPEP
GI- INFLAMMATORY BOWEL AGENTS		
	APRISO	LIALDA
	PENTASA	
	CANASA	
GI- LAXATIVES		
	PREPOPIK	
GROWTH HORMONE		
	NORDITROPIN FLEXPRO	GENOTROPIN
	NUTROPIN AQ	ZOMACTON
OPHTHALMICS, ADRENERGIC AGENTS		
	SIMBRINZA	
OPHTHALMICS ANTIALLERGICS		
	PAZEO	
OPHTHALMIC ANTIBIOTICS - QUINOLONES		
	MOXEZA	
	VIGAMOX	
OPHTHALMIC NSAIDS		
	ILEVRO	
OPHTHALMICS PROSTAGLANDINS		
		TRAVOPROST
OPHTHALMICS STEROID ANTIBIOTIC COMBINATIONS		
	TOBRADEX	TOBRADEX ST
OPHTHALMIC STEROIDS		
	DUREZOL	
PHOSPHATE BINDER AGENTS		
	PHOSLYRA	CALCIUM ACETATE CAP
	RENAGEL	FOSRENOL

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
		VELPHORO
VASOPROTECTANTS		
		CORLANOR

This page intentionally left blank



**Manufacturers' Forum
ANNOUNCEMENT
NorthStar HealthCare Consulting
Georgia Department of Community Health**

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum occurring on Thursday, August 11, 2016.

Date: Thursday, August 11, 2016 from 9am-5pm EST

Location: NorthStar HealthCare Consulting
1121 Alderman Drive, Suite 112
Alpharetta, GA 30005

Appointments: *The Manufacturers' Forum is by appointment only.* Appointments may be requested and will be scheduled **after** the Drugs Under Review are posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Forum. Manufacturers with drugs up for review at the current DURB meeting will be granted preference when seeking appointments. All requests for appointments must be made in writing to GAMedicaid@nhc-llc.com and include the drug name. New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.

Guidelines for Participation:

- To ensure equitable treatment of all manufacturers, individual manufacturer participation shall be limited to one 30-minute time segment per Forum. The presentation shall be limited to approximately 20 minutes with 10 minutes for questions and answers.
- Manufacturer presentations may be audio-recorded for review after the Forum and the associated information shall be presented by NHC in summary fashion at regularly scheduled DURB meetings.
- For new drugs, manufacturers are highly encouraged to present all clinical information pertinent and relevant to current NHC clinical presentations to the DURB, to DCH drug benefit plan design and to other drugs within the class.
- For existing drugs, manufacturers are highly encouraged to present new clinical information since the drug was last reviewed by the DURB, especially clinical information related to comparisons of other drugs within the class.
- An electronic **one-page** summary (front only, font 10, not including references) of each drug presentation, **factually based**, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to GAMedicaid@nhc-llc.com and please include a pronunciation guide of the drug's brand and generic names. The one-page summary along with relevant questions and answers related to the presentation will be provided to the DURB as well as published in the DURB meeting handout that is provided to the public at the meetings and on the DCH website at <http://dch.georgia.gov/durb-meeting-information>.

Comments and Inquiries:

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **Preferred Drug List, Prior Authorization Criteria, Manufacturers' Forum or DURB** should submit these in writing to GAMedicaid@nhc-llc.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **supplemental rebates** should submit these in writing to GOffers@ghsinc.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **claims processing** or **drug benefit plan design** should submit these to the address or phone number below:

**OptumRx, Georgia Department of Community Health
Windward Fairways I, 3025 Windward Plaza Suite 200, Alpharetta, Georgia 30005
Phone: 770-776-2000 Fax: 770-776-2050**

**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

2016

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Tuesday, September 13, 2016: 9:30am – 1:30pm

Tuesday, December 13, 2016: 9:30am – 1:30pm

Manufacturers' Forum

NorthStar HealthCare Consulting

1121 Alderman Drive

Suite 112

Alpharetta, Georgia 30005

Thursday, August 11, 2016: 9:00am – 5:00pm

Thursday, November 10, 2016: 9:00am – 5:00pm

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Gurinder J.S. Doad, Chair	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Deborah W. Fincher, Vice-Chair	R.Ph., M.S.	HIV/AIDS Pharmacy	Pride Medical Pharmacy
Mia Avery	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
M. Celeste Fowler	Pharm.D., HCMBBA	Hospital Pharmacy	Piedmont Henry Hospital
Yolanda P. Graham	M.D.	Child and Adolescent Psychiatry	Devereux Georgia Treatment Network
Mary S. Harris	Ph.D.	Health Care Information/Education Research	BioTechnical Communications, Inc
Burton L. Lesnick	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
Robyn Lorys	Pharm.D.	Managed Care	Peach State Health Plan
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Robert E. Shervette, III	M.D.	Child and Adolescent Psychiatry	Ogeechee Behavioral Health Services
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC